Phreesia, Inc. (NYSE:PHR) General Counsel Sells $103,901.12 in Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 3,496 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $29.72, for a total value of $103,901.12. Following the completion of the sale, the general counsel now directly owns 142,630 shares of the company’s stock, valued at approximately $4,238,963.60. This represents a 2.39 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Phreesia Price Performance

Shares of Phreesia stock opened at $28.20 on Friday. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.64 billion, a PE ratio of -19.18 and a beta of 0.96. The business has a 50 day moving average of $27.29 and a 200 day moving average of $23.84. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $30.53.

Phreesia (NYSE:PHR) last announced its earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $106.80 million during the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.58) earnings per share. As a group, equities research analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

PHR has been the subject of several research reports. Robert W. Baird cut their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Piper Sandler reaffirmed an “overweight” rating and issued a $33.00 target price (up previously from $31.00) on shares of Phreesia in a research note on Wednesday, January 29th. Truist Financial upped their target price on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Citigroup upped their target price on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a research report on Friday, January 10th. Thirteen investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $31.15.

Hedge Funds Weigh In On Phreesia

A number of hedge funds and other institutional investors have recently made changes to their positions in PHR. PharVision Advisers LLC bought a new position in Phreesia in the fourth quarter worth $302,000. Two Sigma Advisers LP bought a new position in Phreesia in the fourth quarter worth $302,000. Silvercrest Asset Management Group LLC raised its holdings in Phreesia by 31.0% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 394,352 shares of the company’s stock worth $9,922,000 after purchasing an additional 93,349 shares in the last quarter. ProShare Advisors LLC raised its holdings in Phreesia by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 15,585 shares of the company’s stock worth $392,000 after purchasing an additional 5,127 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its holdings in Phreesia by 77.1% in the fourth quarter. Nuveen Asset Management LLC now owns 235,827 shares of the company’s stock worth $5,933,000 after purchasing an additional 102,662 shares in the last quarter. Institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.